Seattle Genetics Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
Needham & Company Reiterates Buy Rating on Seattle Genetics (SGEN)
October 30, 2019 7:51 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $121.00 price target on Seattle Genetics (NASDAQ: SGEN) following the company's 3Q earnings report. Seattle had several positive data readouts in 3Q including results from enfortumab vedotin (EV) at ESMO and topline pivotal tucatinib... More
H.C. Wainwright Reiterates Buy Rating on Seattle Genetics (SGEN)
October 30, 2019 7:44 AM EDTH.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $140.00 price target on Seattle Genetics (NASDAQ: SGEN). With ongoing clinical momentum and against the backdrop of strong Adcetris sales, Fein believes Seattle Genetics is building a powerful value-driving structure upon its various assets.... More
Seattle Genetics (SGEN) Misses Q3 EPS by 19c, Revenues Beat; Raises FY19 Revenue Outlook
October 29, 2019 4:14 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q3 EPS of ($0.55), $0.19 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $213.26 million versus the consensus estimate of $211.83 million.
We are executing on our vision of becoming a multi-product global oncology company, recently achieving several important milestones across our late-stage pipeline, said Clay Siegall, Ph.D., President and Chief... More
